List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 59 studies with search of: Open Studies | "Urinary Bladder, Overactive"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting A Study of the Pharmacokinetics and Pharmacodynamics of MK4618 in Women With Overactive Bladder (MK-4618-004)
Conditions: Overactive Bladder;   Overactive Urinary Bladder
Interventions: Drug: MK-4618;   Drug: Tolterodine ER;   Drug: MK-1468 and Tolterodine ER;   Other: Placebo (MK-4618);   Other: Placebo (Tolterodine ER);   Drug: Prophylactic Antibiotic
2 Recruiting A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
Conditions: Overactive Bladder;   Bladder, Overactive;   Overactive Urinary Bladder
Interventions: Drug: Fesoterodine 8 mg;   Drug: Placebo
3 Recruiting Study of Overactive Bladder in Women With Prolapse
Conditions: Urinary Bladder, Overactive;   Pelvic Organ Prolapse
Intervention: Other: Pre- and postoperative evaluations
4 Not yet recruiting Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder
Condition: Urinary Bladder, Overactive
Interventions: Procedure: Unilateral electrode placement and testing;   Procedure: Bilateral electrode placement and testing
5 Recruiting A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM3 EXT1[AM2])
Condition: Urinary Bladder, Overactive
Interventions: Drug: MK-4618 low-dose;   Drug: MK-4618 mid-low dose;   Drug: MK-4618 mid-high dose;   Drug: tolterodine ER;   Drug: Placebo for MK-4618;   Drug: Placebo for tolterodine ER;   Drug: MK-4618 high dose
6 Recruiting A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Alone and in Combination for the Treatment of Overactive Bladder
Conditions: Urinary Bladder, Overactive;   Urinary Bladder Diseases;   Urologic Diseases;   Urological Manifestations;   Signs and Symptoms
Interventions: Drug: Solifenacin succinate and Mirabegron;   Drug: Mirabegron;   Drug: Solifenacin succinate;   Drug: Placebo
7 Recruiting Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder
Condition: Overactive Bladder
Interventions: Behavioral: Dietary Caffeine reduction;   Drug: Anticholinergic medication
8 Unknown † Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Conditions: Urinary Urge;   Urge Incontinence;   Overactive Bladder
Interventions: Drug: solifenacin succinate;   Drug: placebo
9 Not yet recruiting Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
Condition: Overactive Bladder
Interventions: Drug: Solifenacin;   Drug: Oxybutynin
10 Recruiting Painless Laser Therapy for Overactive Bladder
Condition: Overactive Bladder
Intervention: Device: LCT-1000TM (Manufacturer: LiteCure)
11 Unknown † Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder
Condition: Overactive Bladder
Interventions: Drug: Tolterodine extended-release (ER) 4mg;   Drug: Placebo
12 Recruiting Comparative Urine Proteomic Studies of Overactive Bladder in Humans
Condition: Overactive Bladder
Intervention: Drug: fesoterodine
13 Recruiting Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
Condition: Overactive Bladder
Interventions: Drug: Tolterodine ER;   Drug: Placebo
14 Recruiting Grouptraining for Overactive Bladder in Adults
Condition: Overactive Bladder
Interventions: Behavioral: bladdertraining in groups;   Behavioral: bladdertraining individually
15 Recruiting Therapy of the Overactive Bladder Syndrome
Condition: Overactive Bladder
Interventions: Drug: solifenacin;   Procedure: PFMT and WBVT
16 Recruiting Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
Condition: Overactive Bladder
Interventions: Device: (VERV™ System);   Device: Sham version of (VERV™ System)
17 Recruiting Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Condition: Overactive Bladder
Interventions: Drug: Liposome encapsulated botulinum toxin A;   Drug: Normal saline instillation
18 Recruiting A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.
Condition: Overactive Bladder
Interventions: Drug: Tarafenacin 0.2 mg;   Drug: Placebo;   Drug: Tarafenacin 0.4 mg
19 Unknown † Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
Conditions: Overactive Bladder Syndrome;   Voiding Dysfunction
Interventions: Procedure: Cystoscopy;   Procedure: Cystoscopy and urethral dilatation
20 Recruiting Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
Condition: Overactive Bladder in Parkinson's Disease
Interventions: Drug: solifenacin succinate (VESIcare);   Drug: placebo

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services